A purple and pink letter v on a white background.
December 1, 2021

A Comprehensive Guide to Address Your Patients' Acne Concerns

Acne affects up to 50 million Americans annually, making it   the most common skin condition in the United States , and s tudies have shown that 40-55% of adults aged 20 to 40   experience some form of acne .   Over-the-counter topical products for treating acne are big business, with the country   spending over $400 million on them annually . That s   a lot , considering most of those products only address the symptoms of acne, and won t   clear   up the problem for good. If your patients are suffering from blemishes, inflammation, and the scarring that acne can lead to, offer them an effective, long-term solution instead.    

Treating Acne  with  Venus Versa ™  

Venus Versa   performs the most in-demand   aesthetic procedures   popular with patients today. With one workstation, you can carry out non-invasive treatments such as   photorejuvenation / photofacial , acne treatment, hair removal, skin resurfacing, body contouring, cellulite reduction, skin tightening, and wrinkle reduction . The versatility of the device allows you to make the most of your space, while tailoring your offerings to what patients in your area are looking for.   The AC Dual applicator uses I ntense   P ulsed   L ight   to simultaneously address both the cause and visible symptoms of acne , as well as   several   other features for the best patient outcomes.

The AC Dual applicator   uses   innovative   SmartPulse   technology to ensure precise and consistent energy delivery through advanced pulse optimization , delivering p ulses of broad-spectrum light   optimized   for   absor ption   by target chromophores and transformed into therapeutic heat .   For   the   dual-light acne treatment, blue light targets the porphyrin produced by Propionibacterium Acnes bacteria, leading to destruction of the bacteria, while the longer wavelength of   red light   controls inflammation and promotes faster healing . Meanwhile, a r eal-time cooling system   monitors   the light guide temperature 1,000 times a second for unparalleled patient safety and comfort .  

According to a 2016 study, a fifth of those who develop acne will eventually experience acne scarring (upwards of 50 million Americans annually). Unfortunately, this study also makes mention that those with acne scarring were less likely to be found attractive. The good news is that there are options to treating both existing acne and scarring that may develop afterward. 

Treating Acne Scars  with  Venus Viva ™   MD  

Ve nus Viva   MD   is a highly customizable   tabletop   device that delivers exceptional results with low downtime and is safe for all s hades of skin . U sing   NanoFractional   Radio Frequency (RF) with   SmartScan   technology, Venus Viva   MD is a fractional resurfacing system that allows   customized   control of ablation and coagulation for enhanced efficacy in resolving mild to severe skin damage.   Designed with patient satisfaction in mind, it s a n ideal choice for clinicians who are looking for a flexible, powerful skin resurfacing device with a high return on investment. For the treatment of acne scars, Venus Viva   MD has proven to be a safe, effective modality for   Fitzpatrick skin types I VI .  

In a study conducted by Stephen W Eubanks, MD, and James A. Solomon, MD, PhD, subjects aged 22-71   received a series of three treatments to the full face, each 4 weeks apart . The study concluded that fractional radio skin resurfacing with Venus Viva   MD   produced a statistically significant improvement in acne scarring when assessed by independent blinded evaluators. No serious adverse events resulted from treatment by either applicator tip. Treatment pain was low and tolerable among subjects of all Fitzpatrick skin types. Subjects had   high levels   of satisfaction with the results.   ( Click here to read the study in full , and to see before-and-after photos of subject's results.)  

The device has two features that make it especially invaluable for treating acne scars.   The Venus Viva   MD applicator   is easy and ergonomic to use, making skin resurfacing procedures a breeze for you and your staff, as well as your patients. It also comes with   two tip options,   an   80 pin   tip   and   the   160 pin   tip , to make treatments even more   customiz able.   Both tips resurface   the skin using ablation and coagulation,   improving the appearance of   mild to   severe skin conditions.   The   DiamondPolar   applicator uses a combination of Multi-Polar Radio   Frequency (RF) and Pulsed Electro Magnetic Fields   (PEMF)   via our patented (MP) 2 technology.   The unique electrode placement of the   DiamondPolar   applicator allows for treatment around the eyes, along the   jowls, and other smaller areas   that are difficult to treat with less agile applicator models.  

Venus Concept   offers the best technology to deal with today s top aesthetic concerns, and our   industry-unique business model is designed to increase the success of your business   and help you give your patients what they need .   Bring our acne solutions to your clinic today.  

September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
Purple gradient branding graphic for Doublo × Venus Signature Edition
July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.